WO2007149827A3 - Method for modulating the pharmacokinetics and metabolism of a therapeutic agent - Google Patents
Method for modulating the pharmacokinetics and metabolism of a therapeutic agent Download PDFInfo
- Publication number
- WO2007149827A3 WO2007149827A3 PCT/US2007/071510 US2007071510W WO2007149827A3 WO 2007149827 A3 WO2007149827 A3 WO 2007149827A3 US 2007071510 W US2007071510 W US 2007071510W WO 2007149827 A3 WO2007149827 A3 WO 2007149827A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- therapeutic agent
- pharmacokinetics
- metabolism
- modulating
- agent
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01031—Beta-glucuronidase (3.2.1.31)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
This invention is a method for enhancing the activity of a therapeutic agent comprising the administration of the agent in combination with an enzyme, whereby a metabolic pathway of the therapeutic agent is counteracted and the agent's pharmacokinetics and metabolism are modulated.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07812192A EP2037954A4 (en) | 2006-06-20 | 2007-06-19 | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US81522306P | 2006-06-20 | 2006-06-20 | |
US60/815,223 | 2006-06-20 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2007149827A2 WO2007149827A2 (en) | 2007-12-27 |
WO2007149827A3 true WO2007149827A3 (en) | 2009-04-23 |
Family
ID=38834295
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/071510 WO2007149827A2 (en) | 2006-06-20 | 2007-06-19 | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent |
Country Status (2)
Country | Link |
---|---|
EP (1) | EP2037954A4 (en) |
WO (1) | WO2007149827A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102097026B (en) * | 2009-12-14 | 2013-04-10 | 中国科学院上海药物研究所 | Device and method for simulating pharmacokinetics characteristics in vitro |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5877158A (en) * | 1993-09-22 | 1999-03-02 | Behringwerke Aktiengesellschaft | Pro-prodrugs, their production and use |
US5955100A (en) * | 1992-10-27 | 1999-09-21 | Behringwerke Aktiengesellschaft | Prodrugs their preparation and use as pharmaceuticals |
US5985281A (en) * | 1994-12-23 | 1999-11-16 | Zeneca Limited | Chemical compounds |
US20040082639A1 (en) * | 2002-05-15 | 2004-04-29 | Ho Chih Yung | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders |
US20050025709A1 (en) * | 2003-06-13 | 2005-02-03 | Immunomedics, Inc. | D-amino acid peptides |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5279824A (en) * | 1988-04-14 | 1994-01-18 | Merck Patent Gmbh | Pharmaceutical formulation containing heparin and endo-beta-glucuronidase, useful for the treatment of thrombosis |
US20040071685A1 (en) * | 2002-10-09 | 2004-04-15 | Devin Houston | Compositions and methods for increasing the bioavailability of plant polyphenols |
US7871607B2 (en) * | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
WO2006042056A2 (en) * | 2004-10-08 | 2006-04-20 | The Ohio State University | Methods and compositions for enzyme-specific activation of carbohydrate-conjugated prodrugs |
-
2007
- 2007-06-19 EP EP07812192A patent/EP2037954A4/en not_active Withdrawn
- 2007-06-19 WO PCT/US2007/071510 patent/WO2007149827A2/en active Application Filing
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5955100A (en) * | 1992-10-27 | 1999-09-21 | Behringwerke Aktiengesellschaft | Prodrugs their preparation and use as pharmaceuticals |
US5877158A (en) * | 1993-09-22 | 1999-03-02 | Behringwerke Aktiengesellschaft | Pro-prodrugs, their production and use |
US5985281A (en) * | 1994-12-23 | 1999-11-16 | Zeneca Limited | Chemical compounds |
US20040082639A1 (en) * | 2002-05-15 | 2004-04-29 | Ho Chih Yung | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders |
US20050025709A1 (en) * | 2003-06-13 | 2005-02-03 | Immunomedics, Inc. | D-amino acid peptides |
Non-Patent Citations (1)
Title |
---|
See also references of EP2037954A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP2037954A4 (en) | 2011-09-14 |
WO2007149827A2 (en) | 2007-12-27 |
EP2037954A2 (en) | 2009-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1217482A1 (en) | Enzyme modulators and treatments | |
IL209979A (en) | Use of hsp 70 for the preparation of a medicament for the treatment of a lysosomal storage disorder | |
WO2007146426A3 (en) | Nanoshells for drug delivery | |
WO2007002390A3 (en) | Compositions and methods for modulation of smn2 splicing | |
EP1740197A4 (en) | Therapeutic enzyme formulations and uses thereof | |
WO2005111238A3 (en) | Aptamer-mediated intracellular delivery of therapeutic oligonucleotides | |
WO2007019554A3 (en) | Polysaccharides for delivery of active agents | |
WO2008112525A3 (en) | Treatment of lysosomal storage diseases | |
EP1463512A4 (en) | Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes | |
WO2007005941A3 (en) | Liver targeted conjugates | |
EP2002841A4 (en) | Ophthalmic composition comprising xanthan gum and glucose | |
WO2009132050A3 (en) | Auris formulations for treating otic diseases and conditions | |
PT1720872E (en) | Aryl and heteroaryl-piperidinecarboxylate derivatives, the preparation and the use thereof in the form of faah enzyme inhibitors | |
WO2000061192A3 (en) | Methods and compositions for the treatment of pancreatitis | |
WO2006041641A3 (en) | Therapeutic agents with decreased toxicity | |
WO2006124892A3 (en) | Modulators of alpha-synuclein toxicity | |
WO2005108428A3 (en) | Cd40 splice variants and their uses | |
WO2005074655A3 (en) | Materials and method for promotion of nerve regeneration | |
WO2008063768A3 (en) | Compositions and methods for treating metabolic diseases | |
WO2007087154A3 (en) | Methods for enhancing therapeutic effects of a neurotoxin | |
WO2005105081A3 (en) | Therapeutic formulations of desoxyepothilones | |
WO2005045055A3 (en) | The use of plp with peg-rmetase in vivo for enhanced efficacy | |
WO2007002131A3 (en) | Galk1s as modifiers of the pten/akt pathway and methods of use | |
WO2007149827A3 (en) | Method for modulating the pharmacokinetics and metabolism of a therapeutic agent | |
WO2007041397A3 (en) | Targeted pharmaceuticals and ligands |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07812192 Country of ref document: EP Kind code of ref document: A2 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007812192 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |